Unknown Company Form SCHEDULE 13D — Oct 2, 2026
OrbiMed entities filed a Schedule 13D disclosing beneficial ownership of 14,913,764 shares, or approximately 14%, of ADARx Pharmaceuticals' common stock as of September 28, 2026.
Key figures
- Lockup Period
- 180 days after final IPO prospectus
- Oip ii shares
- 9292025
- Genesis shares
- 588235
- Oip ii percent
- 8.7%
- Opi vii shares
- 14325529
- Genesis percent
- 0.6%
- Opi vii percent
- 13.4%
- Shares Outstanding
- 106801325
- Percent Of Aggregate Group
- 14%
- Ipo Purchase Price Per Share
- $17.00
- Preferred Conversion Ratio
- 1-for-1.1717 reverse split basis
- Aggregate Shares Beneficially Owned
- 14913764
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.